Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guides
Guidance and tools
Shares
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks Stock plan guidance
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
FTSE 100 movers: GSK surges on Zantac ruling; Ashtead falls
(Sharecast News) - London's FTSE 100 was up 0.1% at 7,526.03 in afternoon trade on Wednesday. GSK surged to the top of the index after a US court ruled in the pharmaceutical company's favour in a case claiming that its former Zantac heartburn drug caused cancer. Haleon, which was recently spun off from GSK, also jumped.
Barclays upgraded Haleon to 'overweight' from 'equalweight' after the court ruling.
"Zantac related MDL litigation in the US was summarily dismissed last night, meaning it will not proceed to trial (unless successfully appealed)," the bank said. "As such we regard Zantac as substantially derisked, leaving Haleon investible again for those without the appetite for pharma litigation risk."
Smurfit Kappa was also in the black as it announced the buyback of up to 1.2m shares.
Equipment rental firm Ashtead was the worst performer on the index, having gained on Tuesday after results.
FTSE 100 - Risers
GSK (GSK) 1,505.40p 8.47% Ocado Group (OCDO) 688.60p 3.99% Haleon (HLN) 305.00p 3.32% Smith (DS) (SMDS) 317.50p 2.78% Smurfit Kappa Group (CDI) (SKG) 3,048.00p 2.28% Smith & Nephew (SN.) 1,092.50p 1.91% Mondi (MNDI) 1,489.50p 1.46% Frasers Group (FRAS) 897.00p 1.41% AstraZeneca (AZN) 11,296.00p 1.31% Dechra Pharmaceuticals (DPH) 2,714.00p 1.27%
FTSE 100 - Fallers
Ashtead Group (AHT) 4,913.00p -3.06% BT Group (BT.A) 117.65p -2.20% RS Group (RS1) 918.50p -2.18% Rolls-Royce Holdings (RR.) 91.66p -1.96% Glencore (GLEN) 545.70p -1.87% Centrica (CNA) 92.96p -1.86% Halma (HLMA) 2,123.00p -1.71% Harbour Energy (HBR) 304.10p -1.68% Prudential (PRU) 1,058.50p -1.67% WPP (WPP) 845.20p -1.42%
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Diversity, Equity & Inclusion Reports | Doing Business with Fidelity | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Staying secure | Statutory and Regulatory disclosures | Whistleblowing programme
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document or Product Summary document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.
